SciCombinator

Discover the most talked about and latest scientific content & concepts.

Abstract
Ibrutinib shows superiority over obinutuzumab with chlorambucil (G-Clb) in untreated patients with chronic lymphocytic leukemia with comorbidities who cannot tolerate fludarabine-based therapy. However, ibrutinib is relatively more expensive than G-Clb. In this study we evaluated the cost-effectiveness of ibrutinib compared with G-Clb from the United Kingdom (UK) health care perspective.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
0
Concepts
Constitutional monarchy, England, Decolonization, Health care, Health economics, Medicine, United Kingdom, Leukemia
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com